Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ista Pharmaceuticals has filed a new drug application with the FDA for its investigational combination drug T-Pred as a treatment for inflammatory ocular conditions.
Subscribe to our email newsletter
The drug combines the ophthalmic steroid prednisolone acetate with the antibiotic solution prednisolone. Both compounds are commonly prescribed by ophthalmologists, according to Ista Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of unique and uniquely improved ophthalmic products.
“If approved, we believe T-Pred will offer patients a powerful new treatment combining fast anti-inflammatory relief with excellent antibacterial coverage,” stated Dr Vicente Anido, president and CEO of Ista Pharmaceuticals. “Pending acceptance and timely approval of our T-Pred new drug application (NDA) submission, we anticipate a potential launch of this product in mid-2007.”
The company estimates 2005 sales in the US topical ophthalmic anti-inflammatory market to exceeded $400 million, with total prescriptions of approximately 8.8 million.